

Panavance Therapeutics

A clinical-stage pharmaceutical company advancing the development of **GP-2250**, **a truly novel cancer therapeutic.**

 \bigcirc



 \bigcirc

 \bigcirc

New hope begins with novel science.

At Panavance, we're on a mission to provide both.

Panavance's purpose is to give every patient the best possible chance to live a healthy and cancer-free life.

Established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, we are wholly focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them.

Based on truly novel science that disrupts cancer's primary source of energy to bring about cancer cell death, our GP-2250 therapeutic has the potential to transform the treatment of diverse oncological conditions, among other

disease states. We're excited about our preclinical and early clinical results, and are committed to bringing GP-2250 to patients everywhere. But realizing its full potential of any therapeutic takes a village.

That's why we've assembled a leadership team, board of directors, and clinical and scientific advisory boards that include some of the brightest and most capable minds in the life sciences arena, with diverse backgrounds in pharmaceutical drug development, clinical and medical sciences, commercialization, and capital markets.

Join us on our quest improve and extend the lives of cancer patients. At Panavance, we're onto something groundbreaking.

It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, but has truly unique science that provides new hope in the fight against cancer.

> DR. ANUP KASI, University of Kansas Medical Center, GP-2250 Phase 1/2 Principal Investigator

This is **GP-2250**.

A novel oncology therapeutic **with a unique mechanism of action**.

GP-2250 is a broadly active, tumor cell selective cancer therapeutic that suppresses cancer cells by disrupting their energy metabolism production—bringing about cancer cell death. **Here are some of** the things you shoud know about GP-2250.



Tumor-type agnostic, delivering broad utility across cancer etiologies



Tumor cell selective, specifically targeting the energy metbolism of cancer cells



Demonstrating **powerful synergies** with existing cancer treatments

A look inside the novel science that powers GP-2250's mechanism of action.

Normal cells and cancer cells generate energy differently. GP-2250 takes advantage of that difference by decreasing GAPDH and aKGDH, two processes cancer cells rely on.

This paired reduction causes a significant decrease in ATP, **resulting in an** oxidative and metabolic energy crisis for the cancer cell.





Generating **encouraging Early Phase 1 clinical data**



Patent-pending, with a unique and proprietary mechanism of action

GP-2250

3 AMPK is activated and the transcription factor NFkB is inhibited, **generating** metabolic stress. Reactive oxygen species increases, generating oxidative stress. The metabolic and oxidative stress brought on by the energy crisis created by GP-2250 results in apoptotic cell death.





What's in a name?

Our name captures our deep commitment and the broad potential of our therapeutic **Here's how.**



PAN-DISEASE

GP-2250 may offer a broad benefit across and beyond cancers and in combination with existing treatments.



PAN-CREATIC

Today, our initial clinical trials are focused on treating pancreatic cancer—a condition with a clear unmet need.



PAN-THERAPEUTIC

GP-2250 has wide therapeutic potential across stages of disease including before, during, and after surgery, and for maintenance therapy in advanced disease.



PAN-AVANCE

It is our purpose to advance the effectiveness of cancer treatments and improve the quality of life for patients everywhere.

We are **Panavance**.

Disrupting cancer's energy. **Giving patients new hope.**

Visit Panavance.com to learn more.







1055 Westlakes Drive, Ste. 300 Berwyn, PA 19312

Panavance.com

+1.610.922.1910